



ADR

Tip of the Month

Amiodarone – Use in pregnancy and in newborns

Health Canada recently published a summary safety review on intravenous amiodarone use. Physicians should be aware that:

- Amiodarone is a Category D drug in pregnancy. It has been shown to cause congenital hypo- and hyperthyroidism in neonates. Use should be limited to cases where the potential benefit to the mother justifies the risk to the fetus.
- The safety and effectiveness of amiodarone in paediatric patients have not been established. Known risks, including hypotension, bradycardia, and atrioventricular block, appear to be more common dose-related adverse reactions in children than in adults.

For more information:

<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-amiodarone-intravenous-assessing-potential-risk-side-effects-fetuses-newborns.html>

***Please report all suspected
adverse drug reactions (ADRs).***